Fingolimod
Fingolimod, Gilenya
Sphingosine 1-phosphate Receptor Modulator
NADAC/unit
$4.7855
No Shortage
Tier 1: 18.8%
PA Req: 78.7%
14 Manufacturers
14 ANDAs
indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patient....
vs. brand Fingolimod: Generic saves up to 52% per unit
Market Intelligence
2023-07-26 Class II Recall: Ascend Laboratories, LLC
Generic Manufacturers
ACCORD HEALTHCARE INCALKEM LABORATORIES LTDAPOTEX INCAUROBINDO PHARMA LTDBIOCON LTDBIONPHARMA INCDR REDDYS LABORATORIES LTDEZRA VENTURES LLCGLENMARK PHARMACEUTICALS LTDHEC PHARM CO LTDHETERO LABS LTD UNIT VNOVARTIS PHARMACEUTICALS CORPPRINSTON PHARMACEUTICAL INCTEVA PHARMACEUTICALS USA INCZYDUS PHARMACEUTICALS USA INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.